AddLife AB
STO:ALIF B

Watchlist Manager
AddLife AB Logo
AddLife AB
STO:ALIF B
Watchlist
Price: 137.1 SEK 0.22%
Market Cap: 16.7B SEK
Have any thoughts about
AddLife AB?
Write Note

AddLife AB
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

AddLife AB
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
AddLife AB
STO:ALIF B
Note Receivable
kr66m
CAGR 3-Years
111%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genovis AB
STO:GENO
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedCap AB (publ)
STO:MCAP
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Magle Chemoswed Holding AB
STO:MAGLE
Note Receivable
kr606k
CAGR 3-Years
82%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
No Stocks Found

AddLife AB
Glance View

Market Cap
16.7B SEK
Industry
Life Sciences Tools & Services

AddLife AB, a prominent player in the life sciences sector, intricately weaves its narrative through a commitment to enhancing healthcare and laboratory services across Europe. Founded in Sweden, the company has established itself as a crucial intermediary, effectively bridging the gap between manufacturers of medical devices and the healthcare institutions that require them. AddLife operates by acquiring and developing niche companies within two core segments: Labtech and Medtech. Through Labtech, it supplies essential equipment, instruments, and consumables for diagnostic and research laboratories. In Medtech, it provides a variety of healthcare logistics, medical products, and services to hospitals and care facilities, enhancing their operational efficiencies. The financial heartbeat of AddLife rests on its adeptness at creating value through strategic acquisitions and organic growth, capitalizing on the increasing demand for innovative healthcare solutions. By continuously expanding its product portfolio and enhancing the capabilities of its subsidiaries, AddLife ensures a diversified revenue stream, mitigating risks associated with dependence on any single product or market. This approach not only fortifies their market position but also fuels their profit margins, as they deftly respond to shifting industry demands and regulatory changes. The company's shared values and decentralized business model promote entrepreneurship within its subsidiaries, fostering an environment where innovation can thrive—ensuring their continued success and substantial contribution to the evolving landscape of healthcare.

ALIF B Intrinsic Value
158.15 SEK
Undervaluation 13%
Intrinsic Value
Price

See Also

What is AddLife AB's Note Receivable?
Note Receivable
66m SEK

Based on the financial report for Dec 31, 2023, AddLife AB's Note Receivable amounts to 66m SEK.

What is AddLife AB's Note Receivable growth rate?
Note Receivable CAGR 3Y
111%

Over the last year, the Note Receivable growth was -22%. The average annual Note Receivable growth rates for AddLife AB have been 111% over the past three years .

Back to Top